COMMUNIQUÉS West-GlobeNewswire

Thousands of people march to protest Ford’s hospital privatization, Demand he return that funding to our public hospitals
28/05/2026
TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- They are coming from towns across the province, where their local hospitals have been pushed into deficit and forced by the Ford government to make cuts. They are coming in the [...]
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
28/05/2026
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that [...]
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
28/05/2026
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical- [...]
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
28/05/2026
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates [...]
BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026
28/05/2026
BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumors Both safety profile and efficacy data to be highlighted in methylated and [...]
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
28/05/2026
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring [...]
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
28/05/2026
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that [...]
Premium Craft Cannabis Brand Broken Coast Launches Cherry Ztripez Flower and Pre-Rolls for Summer
28/05/2026
New Broken Coast Summer Launch Expands the Brand’s Premium Craft Lineup Alongside an Elevated Packaging Redesign TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; [...]
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
28/05/2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
TREOS Bio Appoints Sunjeet Sawhney as Chief Executive Officer
28/05/2026
Former Rappta Therapeutics CEO and Ipsen Global Oncology Franchise Head joins as TREOS advances its off-the-shelf, biomarker-guided cancer immunotherapy platform and prepares for the next stage of clinical development [...]
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
28/05/2026
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, [...]
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
28/05/2026
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Felix Offers Ozempic at Generic-Level Pricing as Lower-Cost GLP-1 Demand Remains Elevated Across Canada
28/05/2026
Eligible patients can access Ozempic savings through Felix, alongside continued access to Apo-Semaglutide Felix launches Get Started for Free, waiving the initial $99 clinician visit fee at launch; patients pay $149/ [...]
RadNet to Host Men's Health Webinar on June 13, 2026
28/05/2026
Free public event during National Men’s Health Month features leading physicians addressing coronary artery disease, prostate cancer and lung cancer LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: [...]
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
28/05/2026
Freising, Germany, May 28, 2026 (GLOBE NEWSWIRE) -- XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 [...]
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
28/05/2026
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation [...]

Pages